Thursday, April 27th, 2017
11:00AM – 11:45AM PT
Struggling with CRISPR gene editing in primary cells, stem cells or challenging cell lines? Working with challenging genomic targets?
Unlike single guide RNAs (sgRNAs) derived from conventional methods like plasmids and/or in vitro transcription (IVT), synthetic sgRNA can be chemically modified to provide:
- protection from intracellular immune responses found in primary & stem cells
- additional in vivo stability for challenging cell lines and genomic targets
- protection from exonuclease activity present in some cell types
Join us as we discuss why researchers & scientists focused on CRISPR therapeutics, stem cells, and immunotherapy have increasingly turned to chemically modified synthetic sgRNAs for their CRISPR gene editing.
You’ll learn how how well modified synthetic sgRNAs perform with editing challenging cell lines & genomic targets, and enable superior gene editing efficiency & gene editing consistency along with the lowest levels of cytotoxicity when compared to other solutions…all at a competitive cost.
|Kevin Holden, PhD | Head of Synthetic Biology, Synthego
As Head of Synthetic Biology at Synthego, Kevin is responsible for integrating synthetic biology workflows, like CRISPR genome engineering, into novel engineering and automation platforms. He has over 10 years experience that includes synthetic biology and engineering metabolic pathways in microbes. Kevin earned his PhD in Microbiology from UC Davis.